beria Pharmaceuticals India IPO

Iberia Pharmaceuticals India Limited IPO is a Book Building Issue consisting solely of a Fresh Issue of up to 64.76 lakh equity shares.

The equity shares are proposed to be listed on NSE and BSE. Turnaround Corporate Advisors Private Limited is the Book Running Lead Manager, and Bigshare Services Private Limited is the Registrar to the Issue. Key details, including IPO dates, IPO price band, and lot size, are yet to be announced.

About Iberia Pharmaceuticals India Limited

Iberia Pharmaceuticals India Limited was incorporated on March 30, 2013, as Satnam Medical Agencies Private Limited under the Companies Act, 1956. The company subsequently changed its name to Iberia Pharmaceuticals India Private Limited pursuant to a shareholders' resolution dated August 11, 2023.

It was converted into a public limited company under its present name, Iberia Pharmaceuticals India Limited, following a fresh certificate of incorporation dated July 15, 2024. The company is engaged in the marketing, distribution, and sale of pharmaceutical, derma cosmetic, and wellness products in India and selected international markets, with a focus on aesthetic dermatology, skin care, hair care, cardio diabetic care, and general therapeutics.

The company operates in India's pharmaceutical and derma cosmetics industry, offering a portfolio of prescription-based pharmaceutical products, healthcare professional-recommended products, and over-the-counter solutions.

Its product portfolio comprises six brands: Sesderma, Mediderma, Noreva, Dermpix, KeyCi, and Metacare. Dermpix, KeyCi, and Metacare are its proprietary brands, while Sesderma and Mediderma originate from Spain and Noreva originates from France, for which the company has exclusive distribution arrangements. Its dermatology portfolio includes products addressing hyperpigmentation, acne, skin aging, wrinkles, skin rejuvenation, hair loss, and other skin and hair care concerns. Its flagship brand, Sesderma, incorporates specialized formulation technologies, including nanotechnology and liposomal formulations. The cardio diabetic portfolio is marketed under Metacare and includes products addressing hypertension, dyslipidaemia, diabetes, and nutritional deficiencies.

The company follows an asset-light business model and primarily relies on third-party contract manufacturers for the production of its proprietary brands. As of March 31, 2026, it engaged 16 third-party manufacturers for producing its products. These manufacturers are selected based on their manufacturing capabilities, quality management systems, regulatory approvals, and cost-effectiveness.

The company generally enters into manufacturing agreements for periods ranging from two to five years. Its proprietary brands, namely Dermpix, KeyCi, and Metacare, are manufactured according to its specifications and quality requirements. The company oversees quality assurance and regulatory compliance, including the inspection of raw materials, packaging materials, manufacturing processes, and finished products. Its foreign brands, including Sesderma, Mediderma, and Noreva, are manufactured by their respective brand owners and procured through authorized distribution arrangements or direct imports. The company is also developing its own manufacturing capabilities as part of its expansion strategy.

Iberia Pharmaceuticals India has established a nationwide distribution network comprising 472 stockists as of March 31, 2026. Its distribution operations are supported by a network of stockists and medical representatives who promote and market its products to healthcare professionals across multiple states and union territories in India. The company primarily generates revenue from domestic product sales while also exporting products to international markets.

During the last three financial years covered in the prospectus, it exported products to Nepal, Sri Lanka, and Kenya. Additionally, it has exclusive distribution arrangements for Sesderma and Mediderma products across India, Nepal, Bangladesh, Bhutan, Sri Lanka, the United Arab Emirates, and Myanmar. Its products are also available through online marketplaces via its group company, Iberia Skinbrands India Private Limited. The company launched KeyCi in Fiscal 2025 as an online-exclusive proprietary brand marketed through direct-to-consumer channels and e-commerce marketplaces.

The company's operations involve the procurement of finished pharmaceutical and cosmetic products from third-party manufacturers and foreign brand owners rather than operating its own manufacturing facilities. For proprietary brands, third-party manufacturers procure the necessary raw materials and packaging materials from their respective vendors after obtaining the requisite regulatory approvals. The company exercises quality oversight over these manufacturing activities and conducts product-specific evaluations through independent testing laboratories, wherever applicable.

Its quality assurance procedures include dermatological Primary Irritation Patch Tests to assess skin compatibility and in-vivo Sun Protection Factor studies for selected sunscreen formulations. Pharmaceutical products are manufactured by partners holding the requisite licenses and approvals under the Drugs and Cosmetics Act, 1940, while cosmetic products are manufactured in accordance with applicable requirements under the Cosmetic Rules, 2020.

Industry Outlook

• India's aesthetic dermatology market is witnessing significant growth, driven by increasing awareness of skin health, rising disposable incomes, urbanization, and the growing popularity of minimally invasive cosmetic treatments. The market was valued at approximately USD 620 million in Calendar Year 2025 and is projected to reach USD 1,274 million by Calendar Year 2031. Treatments such as Botox, dermal fillers, laser procedures, and high-intensity focused ultrasound are gaining popularity.
• India's dermatology sector covers clinical treatments for skin, hair, and nail conditions, including acne, psoriasis, and other chronic skin disorders. Advancements in biologics, laser therapies, and personalized medicine are transforming treatment approaches. Increasing awareness of skin health, lifestyle changes, and demand for targeted treatments are supporting the expansion of this segment.
• India's derma cosmetics market was valued at approximately USD 453.5 million in Calendar Year 2025, registering a compound annual growth rate of 10% between Calendar Years 2021 and 2025. It is projected to grow at a compound annual growth rate of 16% between Calendar Years 2025 and 2031, reaching approximately USD 1,084.7 million.
• Increasing consumer awareness, changing lifestyles, and growing interest in personal grooming are driving demand for specialized skincare and haircare solutions. Products addressing hyperpigmentation, acne, skin aging, wrinkles, hair loss, and scalp conditions are gaining traction. Millennials and Generation Z are increasingly viewing skincare as an essential part of personal care and overall wellness.
• India's cardio diabetic market reached approximately USD 6,798 million in Calendar Year 2025, registering a compound annual growth rate of 5.7% between Calendar Years 2021 and 2025. The market is projected to grow at a compound annual growth rate of 7.8% between Calendar Years 2025 and 2031, reaching approximately USD 9,919 million. Rising diabetes and cardiovascular disease prevalence, sedentary lifestyles, unhealthy dietary habits, obesity, and increasing urbanization are key growth drivers.
• The growing prevalence of diabetes, hypertension, and dyslipidaemia is supporting demand for long-term pharmaceutical treatments and preventive healthcare solutions.

Iberia Pharmaceuticals India IPO Objectives

The company proposes to utilize the net proceeds from the Issue towards the following objectives:

• Capital expenditure towards the procurement of plant and machinery for the establishment of a manufacturing facility in Haryana.
• Repayment of all or a portion of certain outstanding borrowings availed by the Company.
• Branding and marketing expenses towards enhancing the awareness and visibility of products and brand.
• Funding the working capital requirements of the Company.
• Towards general corporate purposes.

Financial Performance of Iberia Pharmaceuticals India Limited

Iberia Pharmaceuticals India Limited Peer Details Comparison

Strengths and Opportunities of Iberia Pharmaceuticals India IPO

1. The company has a comprehensive portfolio of six brands, including three proprietary brands and three internationally established brands distributed exclusively. Its products cover dermatology, aesthetic care, hair care, cardio-diabetic treatments, and general therapeutics.
2. Exclusive distribution arrangements for international brands such as Sesderma, Mediderma, and Noreva provide access to established products and strengthen the company's presence in the derma cosmetics segment.
3. The company follows an asset-light business model, outsourcing manufacturing to third-party manufacturers and focusing on branding, marketing, and distribution. This enables it to expand its product portfolio without significant investment in manufacturing infrastructure.
4. It has an extensive distribution network comprising 472 stockists and 289 medical representatives as of March 31, 2026, covering 26 states and 5 Union Territories, with additional access to online channels and select international markets.
5. Its proprietary brands offer an opportunity for portfolio expansion. Revenue contribution from proprietary brands increased from 4.13% in FY24 to 14.11% in FY26, indicating growing traction for its in-house brands.
6. The company operates in growing markets. India's derma cosmetics market is projected to increase from USD 453.5 million in CY25 to USD 1,084.7 million by CY31, while the cardio-diabetic market is projected to reach USD 9,919 million by CY31, creating opportunities for business expansion.

Risks and Threats of Iberia Pharmaceuticals India IPO

1. The company derives a significant portion of its revenue from a limited number of brands. Its top two brands contributed 83.96% of revenue in FY26, making it vulnerable to any decline in their sales.
2. The company depends heavily on a few suppliers for foreign brands. Purchases from foreign-brand suppliers accounted for 83.85% of its total stock-in-trade purchases in FY26, creating supplier concentration risks.
3. The company relies entirely on third-party manufacturers for production. The top five manufacturers contributed 80.22% of its purchases from third-party manufacturers in FY26, exposing it to supply disruptions and manufacturing-related risks.
4. A significant portion of revenue comes from Maharashtra and Delhi, which contributed 19.63% and 17.99% of FY26 revenue, respectively. Adverse regional developments could affect sales and distribution.
5. The company faces risks associated with distributing imported products, including regulatory non-compliance, product quality issues, consumer claims, and delays in obtaining necessary approvals from foreign markets.
6. The company depends on third-party distributors, stockists, medical representatives, and online marketplaces to generate sales. Any disruption in these relationships, changes in marketplace policies, or higher service costs could adversely affect its revenue and profitability.

Iberia Pharmaceuticals India IPO Reservation

Iberia Pharmaceuticals India IPO Promoter Holding

The promoters of the company are Nitin Jain, Rishabh Jain, Saurav Ojha, and Shivani Jain.

Iberia Pharmaceuticals India IPO Prospectus

• Iberia Pharmaceuticals India IPO DRHP

Iberia Pharmaceuticals India IPO Registrar and Lead Managers

Iberia Pharmaceuticals India IPO Lead Managers

• Turnaround Corporate Advisors Private Limited

Registrar for Iberia Pharmaceuticals India IPO

Bigshare Services Private Limited

• Contact Number: 8657578989/8069219065/8069219060
• E-mail: ipo@bigshareonline.com

Iberia Pharmaceuticals India IPO Registrar

How To Apply for Iberia Pharmaceuticals India IPO Online?

1. Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
2. Locate the IPO Section: Navigate to the 'IPO' section on the platform.
3. Select IPO: Find and select the Iberia Pharmaceuticals India IPO from the list of open IPOs.
4. Enter the Lot Size: Specify the number of lots you want to bid for.
5. Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
6. Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.

How To Check the Allotment Status of the Iberia Pharmaceuticals India IPO?

Steps to check IPO allotment status on Angel One’s app:

1. Log in to the Angel One app.
2. Go to the IPO Section and then to IPO Orders.
3. Select the individual IPO that you had applied for and check the allotment status.
4. Angel One will notify you of your IPO allotment status via push notification and email.

Don't miss the next investment opportunity - browse the Upcoming IPO on Angel One.

Contact Details of Iberia Pharmaceuticals India IPO

Registered Office: Property No. 4, Block-C, First Floor, Sector-8, Dwarka, Bagdola, Southwest Delhi, New Delhi, Delhi, India, 110077

Phone: +91 9319728265

E-mail: cs@iberiapharmaceuticals.com